Articles - GLP1 drugs changing weight loss and Life & Health insurance


Weight-loss injectables like Wegovy or Ozempic are gaining popularity amid an escalating global obesity crisis. Since 1975, worldwide obesity rates have nearly tripled, with projections indicating that over half of the global population will be overweight or obese by 2035. John Schoonbee, Global Chief Medical Officer, and Adam Strange, Life & Health R&D Manager, elaborate on the impact of GLP-1 drugs on weight loss, metabolic health and insurance. These medications influence risk factors such as insulin resistance, cardiovascular disease, and cancer. Additionally, they discuss the implications of these drugs on Life & Health insurance, including life, critical illness, and disability income, as well as future underwriting risk assessments.

 

Back to Index


Similar News to this Story

Using AI and technology to deliver FCA strategic priorities
Speech by Jessica Rusu, FCA chief data, information and intelligence officer, delivered at the AI and Digital Innovation Summit as part of City Week 2
Climate change pushing insurability to tipping point
With the costs of protection predicted to keep rising with climate risks and become increasingly unsustainable, Scott St. George examines the measures
July 2025 Edition of the Actuarial Post Magazine
With events in the Middle East taking centre stage from the initial air strike on Iran to the eventual US strike and now onto the uneasy ceasefire we

Site Search

Exact   Any  

Latest Actuarial Jobs

Actuarial Login

Email
Password
 Jobseeker    Client
Reminder Logon

APA Sponsors

Actuarial Jobs & News Feeds

Jobs RSS News RSS

WikiActuary

Be the first to contribute to our definitive actuarial reference forum. Built by actuaries for actuaries.